cisplatin

7 · 20 / page

Ask MedXY AI

Latest news

Tag

GastroenterologyBiliary tract cancercisplatin

Durvalumab Plus Chemotherapy Extends Survival in Advanced Biliary Tract Cancer: Insights from the TOPAZ-1 Trial Four-Year Post Hoc Analysis

By MedXY|Jul 12, 2026

A four-year post hoc analysis of the TOPAZ-1 trial confirms that durvalumab combined with gemcitabine and cisplatin offers a long-term survival benefit with manageable safety as first-line treatment for advanced biliary tract cancer.

Urine‑guided Intraoperative Hydration Halves AKI Risk After CRS‑HIPEC with Cisplatin: Randomized Trial Shows Promise

AnesthesiologyAKI

cisplatin

Latest news

Durvalumab Plus Chemotherapy Extends Survival in Advanced Biliary Tract Cancer: Insights from the TOPAZ-1 Trial Four-Year Post Hoc Analysis

Urine‑guided Intraoperative Hydration Halves AKI Risk After CRS‑HIPEC with Cisplatin: Randomized Trial Shows Promise

Lower, More Frequent Cisplatin Dosing Substantially Reduces Hearing Loss in Head and Neck Cancer Without Compromising Short‑Term Survival

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: A 3-Year Survival Update from the Phase III TOPAZ-1 Study

Evaluating the Addition of Polymeric Micellar Paclitaxel to Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: Insights from a Phase 3 Randomized Clinical Trial

Phase III NuTide:121 Trial Shows NUC-1031/Cisplatin Fails to Improve Survival Over Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer

Predicting Chronic Kidney Disease After Cisplatin Treatment: Insights from Population-Level Data